Literature DB >> 25065934

Thymic neuroendocrine tumors.

Paolo Olivo Lausi1, Majed Refai2, Pier Luigi Filosso1, Enrico Ruffini1, Alberto Oliaro1, Francesco Guerrera1, Alessandro Brunelli3.   

Abstract

Thymic neuroendocrine tumors are rare and account for approximately 2% to 5% of all thymic tumors. Despite the suggestion of benign behavior implied by their name, thymic carcinoids have been noted to present a more aggressive biologic behavior than their counterparts in other sites. Because of the lack of data, adequate-sized prospective trials are required for validation, and the enrollment of patients with advanced disease into available clinical trials is encouraged.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Neuroendocrine tumors; Outcome; Radiotherapy; Surgery; Thymus

Mesh：

Year:  2014        PMID： 25065934     DOI： 10.1016/j.thorsurg.2014.05.007

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  9 in total

Review 1.  Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms.

Authors:  Irvin M Modlin; Mark Kidd; Pier-Luigi Filosso; Matteo Roffinella; Anna Lewczuk; Jaroslaw Cwikla; Lisa Bodei; Agnieska Kolasinska-Cwikla; Kyung-Min Chung; Margot E Tesselaar; Ignat A Drozdov
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 2.  Neuroendocrine tumors of the thymus.

Authors:  Pier Luigi Filosso; Enrico Ruffini; Paolo Solidoro; Matteo Roffinella; Paolo Olivo Lausi; Paraskevas Lyberis; Alberto Oliaro; Francesco Guerrera
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

3.  Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group.

Authors:  Pier Luigi Filosso; Xiaopan Yao; Enrico Ruffini; Usman Ahmad; Alberto Antonicelli; James Huang; Francesco Guerrera; Federico Venuta; Dirk van Raemdonck; William Travis; Marco Lucchi; Andreas Rimner; Pascal Thomas; Walter Weder; Gaetano Rocco; Frank Detterbeck; Robert Korst
Journal:  Eur J Cardiothorac Surg       Date:  2016-03-31       Impact factor: 4.191

4.  Multidisciplinary treatment of thymic neuroendocrine tumors: surgery remains a key component.

Authors:  Erin M Corsini; Kyle G Mitchell; Eric L Sceusi; Reza J Mehran; David C Rice; Boris Sepesi; Garrett L Walsh; Stephen G Swisher; Jack A Roth; Ara A Vaporciyan; Wayne L Hofstetter; Mara B Antonoff
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

Review 5.  Ectopic Cushing's syndrome due to thymic neuroendocrine tumours: a systematic review.

Authors:  Fernando Guerrero-Pérez; Inmaculada Peiró; Agustina Pia Marengo; Alex Teulé; José Carlos Ruffinelli; Roger Llatjos; Teresa Serrano; Ivan Macia; Nuria Vilarrasa; Pedro Iglesias; Carles Villabona
Journal:  Rev Endocr Metab Disord       Date:  2021-05-07       Impact factor: 6.514

6.  Invasive atypical thymic carcinoid: three case reports and literature review.

Authors:  Shan Zhu; Zhong-Tang Wang; Wen-Zhi Liu; Shi-Xiang Zong; Bao-Sheng Li
Journal:  Onco Targets Ther       Date:  2016-10-11       Impact factor: 4.147

7.  Neuroendocrine Neoplasms in Rare Locations: Clinicopathological Features and Review of the Literature.

Authors:  Cristina Díaz Del Arco; Javier Sastre; Paloma Peinado; Ángel Díaz; Luis Ortega Medina; Mª Jesús Fernández Aceñero
Journal:  Indian J Endocrinol Metab       Date:  2018 May-Jun

8.  Transformation from Small Cell to Squamous Cell Carcinoma in a Thymic Carcinoma Patient with a Durable Response to Anlotinib: A Case Report.

Authors:  Wenru Qin; Bing Zou; Xinyu Fan; Bingjie Fan; Shijiang Wang; Linlin Wang
Journal:  Cancer Manag Res       Date:  2022-04-29       Impact factor: 3.989

9.  HSP27 and 70 expression in thymic epithelial tumors and benign thymic alterations: diagnostic, prognostic and physiologic implications.

Authors:  S Janik; A I Schiefer; C Bekos; P Hacker; T Haider; J Moser; W Klepetko; L Müllauer; H J Ankersmit; B Moser
Journal:  Sci Rep       Date:  2016-04-21       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.